Patients
catheter-related infection, CKD, inflammatory bowel disease, diarrhea, PD, hyperphosphatemia, diarrhea-predominant irritable bowel syndrome, peritonitis
HYPERPHOSPHATEMIA, INFLAMMATORY BOWEL DISEASE, PERITONITIS
The target population consisted of patients with hyperphosphatemia undergoing PD while being treated with phosphate binders. The main inclusion criteria were as follows: patients aged ≥ 20 years with stable CKD who had undergone PD for ≥ 12 weeks with constant dialysis prescription; were taking phosphate binders at a fixed dosage; had serum phosphorus levels in the range of 3.5–7.0 mg/dL at the screening examination (before washout); patients whose serum phosphorus level increased to 6.1–10.0 mg/dL at 1 week or 2 weeks after the start of washout and from the time of the pre-enrollment examination. The main exclusion criteria were as follows: patients who had concomitantly received HD or hemodiafiltration < 12 weeks before screening, had a history of inflammatory bowel disease or diarrhea-predominant irritable bowel syndrome; were confirmed to have peritonitis, catheter-related infection or catheter malfunction within 4 weeks before screening examination and considered to have difficulty in continuing PD; or had diarrhea or loose stools, defined as a Bristol Stool Form Scale (BSFS) score ≥ 6 and frequency ≥ 3 for ≥ 2 days within 1 week before enrollment. The detailed pre-enrollment and enrollment inclusion and exclusion criteria are included in the Supplementary Materials.